RAC

3.31%

$1.61 race oncology ltd

RAC media coverage, page-2217

First 2217 Last

Share
Profile

Follow
asx11

3,564 Posts.

381

20/06/24

19:50

Post #: 74414224
Share

Originally posted by ReNova: ↑

For those who are worried about the end of 2026 for recruiting timeline.

Hey chatGPT are there any examples of oncology drugs that have been bought out straight after preliminary data in a open label phase 1 clinical trial has been released?

ChatGPT: Yes, there are several examples of oncology drugs that have been acquired after promising preliminary data from open-label Phase 1 clinical trials. Pharmaceutical companies often seek to acquire innovative cancer therapies early in their development based on encouraging early-stage data. Here are a few notable examples:

Loxo Oncology and Bayer:
Drug: LOXO-292 (later named selpercatinib)
Acquisition: Loxo Oncology was acquired by Eli Lilly for approximately $8 billion in 2019, following promising early clinical data, including Phase 1 results.
Details: LOXO-292 showed promising activity against RET fusion-positive cancers in Phase 1 trials, attracting significant interest and leading to the acquisition.

Juno Therapeutics and Celgene:
Drug: JCAR017 (later named lisocabtagene maraleucel or liso-cel)
Acquisition: Celgene acquired Juno Therapeutics for $9 billion in 2018.
Details: The acquisition was driven by positive early-stage data from open-label trials showing the efficacy of JCAR017, a CAR T-cell therapy, in treating B-cell malignancies.

ArQule and Merck:
Drug: ARQ 531
Acquisition: Merck acquired ArQule for $2.7 billion in 2019.
Details: ARQ 531, a BTK inhibitor, showed promising results in Phase 1 trials for treating B-cell malignancies, prompting Merck to make the acquisition.

Immunomedics and Gilead Sciences:
Drug: Sacituzumab govitecan (Trodelvy)Acquisition: Gilead Sciences acquired Immunomedics for $21 billion in 2020.
Details: Early Phase 1/2 data showed significant efficacy in triple-negative breast cancer, leading to the acquisition.

These acquisitions illustrate the high value placed on early promising data in the oncology field and the strategic importance of acquiring innovative therapies to strengthen pharmaceutical companies' oncology portfolios.

I have not checked the details, apparently AI can hallucinate, but the response is encouraging nonetheless.

Expand

Cool story. Have you seen the RAC market cap? Getting bought out at prelim data would be a big L.

Last edited by asx11: 20/06/24

RAC Price at posting: $1.87 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

RHK

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

ASX Market Open: ASX200 to rise for Friday session | July 26

Nine's staff strike as Paris Olympic coverage begins

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

MIN

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

MND

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

NVA

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

HRZ

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

IGO

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

There are more pages in this discussion • 69 more messages in this thread...

First 2217 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.61		Change -0.055(3.31%)		Mkt cap ! $273.4M

Open	High	Low	Value	Volume
$1.66	$1.68	$1.61	$271.5K	166.3K

Buyers (Bids)

No.	Vol.	Price($)
1	1996	$1.61

Sellers (Offers)

Price($)	Vol.	No.
$1.68	1305	2

View Market Depth

No.	Vol.	Price($)
2	4387	1.600
1	31000	1.590
1	10000	1.585
2	8233	1.560
4	15571	1.550

Price($)	Vol.	No.
1.690	585	1
1.700	17181	1
1.750	30400	2
1.755	990	1
1.820	1000	1

Last trade - 16.10pm 26/07/2024 (20 minute delay)

RAC (ASX) Chart

RAC media coverage, page-2217

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

ASX Market Open: ASX200 to rise for Friday session | July 26

Nine's staff strike as Paris Olympic coverage begins

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

RAC media coverage, page-2217

Top Stories

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

ASX Market Open: ASX200 to rise for Friday session | July 26

Nine's staff strike as Paris Olympic coverage begins

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News